# Bradykinin

Canonical source: https://retacompare.com/encyclopedia/bradykinin

Activates B1 (induced by inflammation) and B2 (constitutive) receptors — vasodilation, increased vascular permeability, pain.

Reference facts

Also known asBKCategoryNeuropeptide & OtherMechanism of actionActivates B1 (induced by inflammation) and B2 (constitutive) receptors — vasodilation, increased vascular permeability, pain.TargetsB1R, B2RIndications under research or approvedResearch target (Icatibant, a B2 antagonist, treats hereditary angioedema)Regulatory status (reference entry)Native not approved; antagonists areHalf-life~17 secondsSequenceRPPGFSPFRSequence notesNonapeptide cleaved by kallikreins from kininogen.Molecular weight (Da)1060First reported1949
    Primary References

Marceau & Regoli, Nat Rev Drug Discov 2004 (Kinins)


    Explore research articles about Bradykinin


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Marceau & Regoli, Nat Rev Drug Discov 2004 (Kinins): https://pubmed.ncbi.nlm.nih.gov/15173839/